Ind-Swift Laboratories Ltd
About
IndSwift Laboratories was conceived by the Mehtas, the Munjals, and the Jains in 1986 to revolutionise the pharmaceuticals business. Today, the business has diversified into areas like infrastructure, printing, packaging and stationery, media publication, and education. The pharmaceutical business of the company manufactures 750 active pharmaceutical ingredients (APIs) and finished good dosages in areas like diabetology, cardiology, neurology, oncology, antidepressants, and more. Through its manufacturing facilities in Jammu and Kashmir, Himachal Pradesh, and Haryana, Ind Swift boasts a capacity to produce around 2300 million tablets, 27 million vials, 84 million capsules, and 62 million oral liquid bottles annually. The company’s products, across all its sectors, can be found in over 50 countries today.
Featured In Fortune India Ranking
Financial Data 2024
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 1676 33.7% | 1253 11.7% | 1122 22.4% | 917 11.0% | 825 -7.3% | 891 17.0% | 761 8.1% | 704 5.6% | 667 -0.3% | 669 -27.2% | 918 -20.0% | 1148 -24.7% | 1524 29.1% | 1180 47.0% | 803 19.9% | 670 - |
| Net Operating Income (INR Cr) | 1281 6.10% | 1207 16.23% | 1039 16.54% | 891 14.33% | 780 3.05% | 757 -1.16% | 765 6.88% | 716 9.64% | 653 -1.09% | 660 -31.57% | 965 -15.05% | 1136 -19.38% | 1409 35.88% | 1037 33.48% | 777 33.05% | 584 30.57% |
| Profit (INR Cr) | 421 784.4% | 48 - | -2 - | -3 - | -21 - | 29 31.7% | 22 - | -39 - | -59 - | -119 - | -122 - | -118 - | 89 -0.3% | 89 58.7% | 56 39.6% | 40 - |
| Assets (INR Cr) | 949 -39.2% | 1562 -0.6% | 1571 -3.3% | 1625 -3.7% | 1687 -3.6% | 1751 6.1% | 1650 -7.5% | 1783 -9.7% | 1975 -1.7% | 2008 -3.5% | 2081 -0.6% | 2094 12.5% | 1861 31.6% | 1414 36.4% | 1037 39.6% | 743 - |
| Net Worth (INR Cr) | 931 86.8% | 499 23.3% | 404 3.0% | 393 -5.5% | 416 19.4% | 348 16.3% | 299 13.8% | 263 12.8% | 233 -15.5% | 276 -29.3% | 391 -22.4% | 503 -16.5% | 603 22.7% | 491 37.3% | 358 33.0% | 269 14.2% |
| Employee Cost (INR Cr) | 153 12.5% | 136 6.9% | 127 19.3% | 107 3.7% | 103 5.2% | 98 10.8% | 88 26.5% | 70 4.2% | 67 22.2% | 55 21.8% | 45 10.8% | 41 41.4% | 29 43.5% | 20 0.8% | 20 21.9% | 16 - |
| Interest Cost (INR Cr) | 51 | 92 | 96 | 100 | 107 | 92 | 28 | 88 | 106 | 117 | 117 | 140 | 85 | 56 | 51 | 47 |
| Cash & Bank Balance (INR Cr) | 432 | 18 | 21 | 12 | 11 | 30 | 9 | 16 | 23 | 20 | 21 | 18 | 47 | 54 | 54 | 23 |
| Total Debt (INR Cr) | 17 | 862 | 953 | 1005 | 1031 | 1148 | 1083 | 1242 | 1457 | 1413 | 1355 | 1240 | 1013 | 819 | 588 | 379 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 25.1% | 3.8% | - | - | - | 3.3% | 2.9% | - | - | - | - | - | 5.9% | 7.6% | 7.0% | 6.0% |
| Profit As % Of Assets | 44.4% | 3.1% | - | - | - | 1.7% | 1.3% | - | - | - | - | - | 4.8% | 6.3% | 5.4% | 5.4% |
| Profit As % Of Networth | 45.2% | 9.6% | - | - | - | 8.3% | 7.4% | - | - | - | - | - | 14.8% | 18.2% | 15.8% | 15.0% |
| Interest Cost to EBITDA % | 20.1% | 45.5% | 48.8% | 54.8% | 74.5% | 73.1% | 21.3% | 88.3% | 113.5% | 327.2% | 447.1% | 255.9% | 47.7% | 32.4% | 41.6% | 40.3% |
| Debt to Equity Ratio | 0.02 | 1.73 | 2.36 | 2.56 | 2.48 | 3.30 | 3.62 | 4.72 | 6.25 | 5.12 | 3.47 | 2.46 | 1.68 | 1.67 | 1.64 | 1.41 |
| RONW | 19.3% | 13.2% | - | - | - | -9.5% | 6.9% | - | - | - | - | - | 16.3% | 21.1% | 18.0% | 16.0% |
| ROCE | 20.7% | 14.8% | 0.0% | 0.0% | 0.0% | 3.9% | 4.3% | 0.0% | 0.0% | 0.0% | 0.4% | 2.1% | 11.6% | 12.7% | 13.1% | 16.1% |